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Engineering T cells with chimeric antigen receptors
(CARs) has emerged as a promising approach to adoptive
T cell therapy for cancer. We have been studying CARs
that employ the ligand-binding domain of the NKG2D
receptor to target tumors. NKG2D ligand expression is
increased on the surface of stressed cells, like tumor cells,
making this family of ligands a target of interest for cancer
immunotherapies. Two CARs were constructed: 1) a
fusion of the full-length NKG2D receptor and CD3z
(NKG2Dζ) and 2) the extracellular domain of NKG2D
fused to a second-generation CAR scaffold composed of
transmembrane and intracellular domains from CD28
and the signaling domain of CD3z (NKG2D28ζ). Since
surface expression of NKG2D is limited by the presence
of DAP10, we also created a vector where DAP10 was
co-expressed with NKG2Dζ (NKG2Dζ10). Indeed,
NKG2Dζ10-CAR-T cells displayed a greater than 10-fold
increase in CAR expression compared to NKG2Dζ;
NKG2D28ζ showed an intermediate level of expression.
T cells expressing any of the NKG2D CARs produced
IFNg and TNFa in response to NKG2D ligand stimulation
and efficiently killed tumor targets in vitro. However,
following infusion into syngeneic hosts, we observed
significant toxicity in vivo with these CAR constructs.
Signs of toxicity, including poor body condition, hunched
posture, labored breathing, and decreased core body tem-
perature were observed in tumor-bearing and tumor-free
mice treated with NKG2D-based CAR-T cells as com-
pared to control mice. The severity of NKG2D CAR-T cell
toxicity varied, with NKG2Dζ10 being severely toxic,
NKG2D28ζ showing intermediate toxicity, and NKG2Dζ
being tolerable. Clinical symptoms of toxicity and mortal-
ity rates were exacerbated when mice received chemother-
apy prior to adoptive transfer of T cells expressing any of
the NKG2D CARs. These observations were consistent
between BALB/c and C57BL/6 hosts. Further characteriza-
tion revealed that the toxicity coincided with a systemic
cytokine storm and lethal levels of inflammation within
the lungs. These data warn that extreme caution should
be taken when using NKG2D ligands for targeted immu-
notherapy and demonstrate that enhancing T cell expres-
sion of strongly activating CARs can be detrimental in
vivo when the CAR target is not uniquely expressed on
the tumor.
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